In March 2025, the company announced new designs for a direct-to-shopper supplying of its Wegovy weight loss drug. The company recognized a completely new pharmacy, called NovoCare, which might demand customers $499 a month for access to the drug, less than half the expense of the drug through other pharmaceutical distribution networks.[fifty three